skip to main content

Welcome to Evgen Pharma

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

Evgen Pharma Image Strategy


Evgen Pharma has a clear strategy for driving shareholder value from its technology

Read more

Evgen Pharma Image History


Evgen Pharma has attracted a highly experienced commercial, scientific and advisory team

Read more

Evgen Pharma Image Organisation


Founded in 2007, Evgen Pharma has evolved quickly into a clinical stage company

Read more


Evgen Pharma is owned by its management team, venture capital investors and private individuals. Its largest shareholders are the North West Fund for Biomedical and Enterprise Ventures.

Find out more


Our clinical pipeline is based on our proprietary Sulforadex® platform technology. Phase I studies have been successfully completed and we are progressing two clinical programmes into Phase II. The two programmes – targeting breast cancer and subarachnoid haemorrhage – benefit from from the substantial body of data generated by academic research into sulforaphane.

Breast cancer: the biggest cause of cancer death in women

With more than 1.5 million diagnoses each year worldwide, the successful treatment of breast cancer remains a top priority for medics and pharmaceutical companies alike.

Read more

Subarachnoid haemorrhage (SAH): a recognised orphan indication

SAH accounts for one in every 20 strokes in the UK but during the past two decades no significant clinical advances have been made to combat the condition.

Read more

Other significant programmes in cancer and neurological diseases

Evgen Pharma has a pipeline of programmes to address other cancers, including prostate, and major neurological diseases such as multiple sclerosis.

Read more


The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.

Find out more